Name of the issue: Indegene Limited

1 **Type of issue (IPO/ FPO)** IPO

2 **Issue size (Rs. crore)** 1,841.76
Source: Prospectus dated May 9, 2024

3 **Grade of issue alongwith name of the rating agency**

Name Not Applicable
Grade Not Applicable

4 **Subscription Level (Number of times)** 70.85
Source: Based on valid applications (excluding Anchor investors)

5 **QIB holding (as a %age of total outstanding capital) as disclosed to stock exchanges**

Particulars	%
(i) On Allotment May 10, 2024 (1)	8.89%
(ii) at the end of the 1st Quarter immediately after the listing	7.63%
(iii) at the end of 1st FY (March 31, 2025)	10.20%
(iv) at the end of 2nd FY (March 31, 2026)	18.57%
(v) at the end of 3rd FY (March 31, 2027)(2)	Not available

(1) Source: Basis of Allotment includes allotment to Anchor Investors

(2) QIB Holding not disclosed as reporting for relevant period has not been completed.

6 **Financials of the issuer**

(Consolidated Rs. in crore)

Parameters	1st FY (March 31,2025)	2nd FY (March 31,2026)	3rd FY (March 31,2027)*
Income from operations	2,839.0	3,510.5	Not Available
Net Profit for the period	406.7	401.1	Not Available
Equity capital	47.9	48.1	Not Available
Reserves excluding revaluation reserves	2,567.7	3,090.6	Not Available

*Note: *March 31, 2027 shall be updated in due course*

7 **Trading status in the scrip of the issuer**

Indegene shares are listed on both the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE")

Particulars	Status
(i) at the end of 1st FY (March 31, 2025)	Active
(ii) at the end of 2nd FY (March 31, 2026)	Frequently Traded
(iii) at the end of 3rd FY (March 31, 2027) (1)	Not Available

(1) will be updated in due course

8 **Change, if any, in directors of issuer from the disclosures in the offer document**

Particulars	Name of Director	Appointed / Resigned
at the end of 1st FY March 31, 2025	Krishnamurthy Venugopala Tenneti	Appointed
at the end of 2nd FY March 31, 2026	Neeraj Bharadwaj	Resigned
	Neeraj Bharadwaj	Appointed
	Jily Mary	Appointed
at the end of 3rd FY March 31, 2027 (1)	NA	NA

(1) Information shall be updated in due course

9 **Status of implementation of project/ commencement of commercial production**

Particulars	Remarks
(i) as disclosed in the offer document	Not Applicable
(ii) Actual implementation	
(iii) Reasons for delay in implementation, if any	

10 **Status of utilization of issue proceeds**

(i) as disclosed in the offer document

Expenditure items	Proposed Utilization (Rs cr)	Actual Utilization (Rs cr)
Repayment/prepayment of indebtedness of one of their material subsidiaries, ILSL Holdings, Inc.	391.33	395.00
Funding the capital expenditure requirements of the company and one of their material subsidiaries, Indegene Inc.	102.92	57.77
Technology, Cybersecurity and Cloud infrastructure related cost	0.00	25.26
General corporate purposes and inorganic growth	230.12	229.31
Issue Expenses	35.63	35.40
Total	**760.00**	**742.74**

(ii) Actual utilization	742.74
(iii) Reasons for deviation, if any	Members have passed a special resolution dated August 12, 2025, approving variation in utilization of initial public offering proceeds. A total of Rs. 38.65 crore was carved out from the Object – 'Funding the capital expenditure requirements of the company and one of their material subsidiaries, Indegene Inc.' Out of which, Rs. 3.67 crore was adjusted towards the Object – 'Repayment/prepayment of indebtedness of one of their material subsidiaries, ILSL Holdings, Inc.' on account of excess loan payment due to foreign exchange rate fluctuation and balance Rs. 34.99 crore was allocated to the new Object - 'Technology, Cybersecurity and Cloud infrastructure related cost'

11 **Comments of monitoring agency, if applicable**

(a) Comments on use of funds	Utilization of gross proceeds is in line with the objects of the offer.

(b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document	Members have passed a special resolution dated August 12, 2025, approving variation in utilization of initial public offering proceeds.
(c) Any other reservations expressed by the monitoring agency about the end use of funds	NA

12 **Price-related data**

Designated SE	NSE
Issue Price (Rs.)	452
Listing Date	13-May-24

Price parameters	At close of listing day May 13, 2024	At close of 30th calendar day from listing day	At close of 90th calendar day from listing day)	As at the end of March 31, 2025		
				Closing price	High	Low
Market Price	570.90	561.75	573.40	578.25	736.60	468.90
Nifty 50	22,104.05	23,264.85	24,367.50	23,519.35	26,277.35	21,281.45
Sectoral Index	Not comparable to any of the available sectoral indices					

Price parameters	As at the end of March 31, 2026			As at the end of March 31, 2027[(1)]		
	Closing price	High	Low	Closing price	High	Low
Market Price	434.60	632.90	414.00	-	-	-
Nifty 50	22,331.40	26,373.20	21,743.65	-	-	-
Sectoral Index	Not comparable to any of the available sectoral indices					

Source: Stock Exchange data. Where the 30th day / 90th day/ March 31 of a particular year falls on a holiday, the immediately preceding trading day has been considered

(1) Will be updated in due course. Market price on NSE taken, being the designated stock exchange

30th calendar day shall be taken as listing date plus 29 calendar days. 90th calendar day shall be taken as listing date plus 89 calendar days

13 **Basis for Issue Price and Comparison with Peer Group & Industry Average**

There are no listed companies in India that engage in a business similar to that of the Company. Accordingly, it is not possible to provide an industry comparison in relation to the Company

14 **Any other material information**

Particulars	Date
Announced strategic colloboration with Microsoft to Help Life Sciences Companies Scale Up Generative AI Adoption and Accelerate Business Impact	11-07-24
Re-appointed Mr. Krishnamurthy Venugopala Tenneti as the Independent Director	25-07-24
Indegene announced the financial results for the quarter ended June 30, 2024	01-08-24
Announced the sixth edition of Indegene Digital Summit	10-10-24
Indegene announced the financial results for the quarter ended September 30, 2024	28-10-24
Announced a new delivery center in Hyderabad to strengthen its global delivery operations	18-11-24
Indegene announced the financial results for the quarter ended December 31, 2024	30-01-25
Indegene Expands Footprint in Europe, Launches New Entity in Spain	06-02-25
Indegene Expands Footprint in Europe, Announces New Center in London	19-03-25
Indegene announced the financial results for the quarter ended March 31, 2025	28-04-25
Corporate Identity Number (CIN) of the Company has changed from U73100KA1998PLC102040 to	20-05-25
Annual Report for FY 2024-25	30-05-25
FAST India Collaborates with Indegene to Make Indian Biotech Ecosystem Future-Ready	03-07-25
Resignation of Non-Executive Non-independent Director Mr. Neeraj Bharadwaj	22-07-25
Indegene announced the financial results for the quarter ended June 30, 2025	31-07-25
Indegene has won a Gold at the Brandon Hall Group's HCM Excellence Awards 2025, for its gamified Learningand Development approach	19-08-25
Indegene has expanded its presence in India with the opening of a new center in Pune	05-09-25
Datavant and Indegene Partner to Power More Efficient Clinical Trial Recruitment	19-09-25
Indegene Ireland Limited has, on September 30, 2025, signed a Share Purchase Agreement ("SPA") to acquire 100% equity shares in BioPharm Parent Holding, Inc. along with its subsidiaries	01-10-25
Annual Report for FY 2024-25	16-10-25
Indegene Ireland Limited has signed a Share Purchase Agreement ("SPA") to acquire 100% equity shares in Warn And Co Limited	17-10-25
Indegene announced the financial results for the quarter ended September 30, 2025	30-10-25
Indegene Ireland Limited has today i.e. on 10th November 2025 signed a Share Purchase Agreement ("SPA") to acquire 100% equity shares in Cake Kommunikations Holding GmbH	10-11-25
Announced the appointment Mr. Neeraj Bharadwaj as a Non-Executive Independent Director, for a term of five years effective from 25th Jan 2025	19-12-25
Approved allotment under ESOP Plan 2020 and RSU plan 2020	19-12-25
Ingenes Nomination and Remuneration Committee approved grants of 5,08,368 equity shares of face value of Rs.2 under the RSU 2020 Plan.	31-12-25
Indegene Inc(USA) on December 31, 2025, signed a Share Purchase Agreement (SPA) to acquire 100% equity shares in Trilogy Writing & Consulting Inc.	31-12-25
Announcement regarding step down subsidiary Indegene Aptilon Services Inc.& Trilogy Writing Consulting Inc, amalgamated on January 1st, 2026 to form Indegene Healthcare Canada Inc.	01-01-26
Announced the appointment of Ms. Jilly Mary De Simone as Additional Director for a term of three years effective from January 22, 2026	22-01-26
Scrutinizer's Report and voting results, a special resolution was passed via Postal Ballot to appoint Mr. Neeraj Bharadwaj as a Non-Executive Independent Director.	23-01-26
Indegene's board met to approve and announce the financial results for the quarter ended December 31, 2025.	29-01-26
Indegene Healthcare UK Limited a subsidiary of Indegene Limited acquired two UK-based healthcare consulting firms: DT Associates Research and Consulting Services Limited and Trilogy Writing and Consulting Limited	01-03-26
The Board of Directors approved resolutions for the allotment of shares under the company's RSU 2020 plan	18-03-26
Approved the audited standalone and consolidated financial results for the quarter and year ended March31, 2026, along with Auditor's Report	29-04-26

Source- Stock Exchange filings

For further updates and information, please refer stock exchange websites i.e. www.bseindia.com and www.nseindia.com

DISCLAIMER:

The information disclosed on this website has been uploaded by Citigroup Global Markets India Private Limited ("Citi") solely pursuant to the requirements of the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012 (the “Circular”) for the limited purpose of the Circular, without having regard to specific objectives, suitability, financial situations or the needs of any particular person, and does not constitute any recommendation, and should not be construed as an offer to sell or the solicitation of an offer to buy, purchase or subscribe to any securities mentioned herein. Neither this information, nor anything else contained on this website, shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. Nothing in this information is intended by Citi to be construed as legal, regulatory, accounting, tax or other advice. Past performance is not necessarily a guide for future performance.

The information disclosed on this website has been collated from different sources, including, but not limited to, information obtained from the websites of the BSE Limited (www.bseindia.com), The National Stock Exchange of India Limited (www.nseindia.com), websites of the respective issuer companies, annual reports of the issuer companies, certain databases such as “www.capitalmarkets.com“ and post issue reports filed with Securities and Exchange Board of India. Neither Citi, its affiliates nor any of their respective directors, employees, agents or representatives makes any implicit or explicit representation or warranty regarding the accuracy or completeness of the information or accepts or assumes any responsibility for the accuracy or completeness of the information or any loss whether direct or indirect, incidental, special or consequential that may arise from or in connection with the use of this information or otherwise.

The information disclosed on this website is updated as of May 26, 2026. Citi does not undertake to update the information contained herein except as required by applicable law or regulation.